(Q38983353)

8 September 2017

The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro (English)

1 reference

8 September 2017

Philine Schneider

1

1 reference

8 September 2017

Margarete Schön

2

1 reference

8 September 2017

Nadin Pletz

3

1 reference

8 September 2017

Cornelia S Seitz

4

1 reference

8 September 2017

Ningshu Liu

5

1 reference

8 September 2017

Karl Ziegelbauer

6

1 reference

8 September 2017

Karolin Zachmann

7

1 reference

8 September 2017

Steffen Emmert

8

1 reference

8 September 2017

Michael P Schön

9

1 reference

8 September 2017

1 August 2014

1 reference

8 September 2017

Experimental Dermatology

1 reference

8 September 2017

23

1 reference

8 September 2017

579-584

1 reference

8 September 2017

8

1 reference

Resistance to RAF inhibitors revisited

8 September 2017

1 reference

Tumor adaptation and resistance to RAF inhibitors

21 January 2018

1 reference

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

Drug-resistance in human melanoma

21 January 2018

1 reference

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

Ipilimumab and vemurafenib: two different routes for targeting melanoma.

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets

21 January 2018

1 reference

Current clinical overview of cutaneous melanoma

21 January 2018

1 reference

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

21 January 2018

1 reference

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells

21 January 2018

1 reference

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models

21 January 2018

1 reference

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

21 January 2018

1 reference

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

21 January 2018

1 reference

PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes

21 January 2018

1 reference

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

Understanding melanoma signaling networks as the basis for molecular targeted therapy

21 January 2018

1 reference

Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells.

21 January 2018

1 reference

PI3K/PTEN signaling in angiogenesis and tumorigenesis

21 January 2018

1 reference

MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop

21 January 2018

1 reference

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

21 January 2018

1 reference

[Kinase inhibitors for the therapy of malignant melanoma].

21 January 2018

1 reference

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma

21 January 2018

1 reference

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

The role of the PI3K-AKT pathway in melanoma

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

Phosphatidylinositol-3-kinase as a therapeutic target in melanoma

21 January 2018

1 reference

Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.

21 January 2018

1 reference

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

21 January 2018

1 reference

Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice

21 January 2018

1 reference

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

21 January 2018

1 reference

Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor

21 January 2018

1 reference

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EXD.12470

1 reference

8 September 2017

1 reference